Jefferies Financial Group Inc. Increases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Jefferies Financial Group Inc. grew its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 141.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 96,849 shares of the medical equipment provider's stock after purchasing an additional 56,742 shares during the quarter. Jefferies Financial Group Inc.'s holdings in Hologic were worth $6,982,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Principal Financial Group Inc. increased its position in shares of Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock valued at $19,547,000 after acquiring an additional 1,606 shares during the last quarter. Nisa Investment Advisors LLC increased its position in shares of Hologic by 44.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock valued at $4,595,000 after acquiring an additional 19,688 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its position in shares of Hologic by 11.4% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 68,427 shares of the medical equipment provider's stock valued at $4,933,000 after acquiring an additional 6,986 shares during the last quarter. Groupama Asset Managment increased its position in shares of Hologic by 63.4% during the fourth quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock valued at $3,918,000 after acquiring an additional 21,037 shares during the last quarter. Finally, Olstein Capital Management L.P. increased its position in shares of Hologic by 5.9% during the fourth quarter. Olstein Capital Management L.P. now owns 90,000 shares of the medical equipment provider's stock valued at $6,488,000 after acquiring an additional 5,000 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Stock Performance

Shares of Hologic stock traded down $0.82 during trading hours on Friday, reaching $62.10. The company had a trading volume of 5,375,411 shares, compared to its average volume of 2,269,540. The firm has a market cap of $13.84 billion, a PE ratio of 19.59, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The business has a fifty day simple moving average of $58.14 and a 200 day simple moving average of $65.98. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm's quarterly revenue was down 1.2% on a year-over-year basis. During the same quarter last year, the company earned $1.03 earnings per share. On average, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity at Hologic

In other Hologic news, Director Martin D. Madaus acquired 5,445 shares of the company's stock in a transaction that occurred on Wednesday, May 7th. The stock was bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.88% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Argus downgraded Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Evercore ISI decreased their target price on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a research report on Friday, May 2nd. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Morgan Stanley decreased their target price on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Finally, Leerink Partnrs downgraded Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Twelve equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Hologic currently has a consensus rating of "Hold" and a consensus target price of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.